Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$53.01 USD
+2.24 (4.41%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $53.10 +0.09 (0.17%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth B Momentum D VGM
Viking Therapeutics, Inc. (VKTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$114.67 | $138.00 | $90.00 | 125.86% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Viking Therapeutics, Inc. comes to $114.67. The forecasts range from a low of $90.00 to a high of $138.00. The average price target represents an increase of 125.86% from the last closing price of $50.77.
Analyst Price Targets (9 )
Broker Rating
Viking Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on 10 recommendations.
Of the 11 recommendations deriving the current ABR, 11 are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/VKTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 10 | 10 | 9 | 9 |
Buy | 0 | 0 | 0 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.10 | 1.10 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/24/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
6/16/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
6/4/2024 | Maxim Group | Naz Rahman | Strong Buy | Strong Buy |
6/4/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
5/16/2024 | Raymond James | Steven Seedhouse | Moderate Buy | Strong Buy |
3/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/15/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
2/23/2024 | William Blair | Andy T Hsieh | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 11 |
Average Target Price | $113.70 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 252 |
Current Quarter EPS Est: | -0.26 |